Free Trial

Eterna Therapeutics Q4 2022 Earnings Report

Eterna Therapeutics logo
$0.31 -0.02 (-7.08%)
As of 02/21/2025 04:00 PM Eastern

Eterna Therapeutics EPS Results

Actual EPS
-$1.24
Consensus EPS
-$2.40
Beat/Miss
Beat by +$1.16
One Year Ago EPS
N/A

Eterna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eterna Therapeutics Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Eterna Therapeutics Earnings Headlines

Eterna appoints Zeldis, Sather to scientific advisory board
A strange twist 500 miles from Washington
Energy is life. And this year, it could also make national heroes out of President Trump and VP Vance. With the news cycle dominated by the tariffs… Elon’s DOGE… and the Russia peace talks… Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard – in the heart of Appalachia.
Eterna Therapeutics Appoints Dr. Elena Ratner To Board Of Directors
See More Eterna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eterna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eterna Therapeutics and other key companies, straight to your email.

About Eterna Therapeutics

Eterna Therapeutics (NASDAQ:ERNA), a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Eterna Therapeutics Profile

More Earnings Resources from MarketBeat